Picoplatin (interim results and clinical trials)

http://www.clinicaltrials.gov/ct/show/NCT00116610
Picoplatin as Second-Line Therapy for Patients With Small Cell Lung
Cancer
This study is ongoing, but not recruiting participants.

Sponsored by: Poniard Pharmaceuticals
Information provided by: Poniard Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00116610
Purpose

This is a Phase II research study that is designed for patients who have
small cell lung cancer (SCLC) that is no longer responding to treatment.
Patients will receive picoplatin, a new platinum-based agent that is
currently under investigation, in 21-day cycles.
------------------------------------------------------------------------------------

Poniard reports positive results for lung cancer drug
Associated Press 04.23.08, 3:50 PM ET

SOUTH SAN FRANCISCO, Calif. - Poniard Pharmaceuticals Inc. said Wednesday
its lung cancer drug picoplatin continued to extend patient survival in
mid-stage studies.

The company said the latest results confirmed older findings in patients
with small cell lung cancer who did not respond to chemotherapy or whose
cancer progressed despite other initial treatments.

Cancer patients taking picoplatin lived a median of 27 weeks, the company
said, compared with 14 weeks of survival for patients undergoing standard
care.

Poniard said it plans to continue testing its drug in late-stage trials
with a launch goal of 2010.

------------------------------------------------------------------------------------

http://www.clinicaltrials.gov/ct2/show/NCT00465491

Study of Picoplatin Efficacy After Relapse (SPEAR)

This study is currently recruiting participants.
Verified by Poniard Pharmaceuticals, September 2007

Sponsored by: Poniard Pharmaceuticals
Information provided by: Poniard Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00465491
Purpose

Picoplatin is a new type of platinum drug that has been investigated in
several clinical trials, and may provide an improved safety profile over
current treatment options. This study is designed to compare the efficacy
and safety of picoplatin plus Best Supportive Care (BSC) with BSC alone.
Best Supportive Care includes care and treatment to optimize the comfort
of patients and their ability to function, as well as to minimize the
side-effects of anti-cancer treatments.

Official Title: A Randomized, Controlled Phase III Trial of Picoplatin
and BSC Versus BSC Alone in Patients With Small Cell Lung Cancer (SCLC),
Refractory or Progressive Within Six Months of Completing First-Line,
Platinum-Containing Chemotherapy.

------------------------------------------------------------------------------------

http://www.clinicaltrials.gov/ct2/show/NCT00465725
A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects
With Solid Tumors

This study is currently recruiting participants.
Verified by Poniard Pharmaceuticals, April 2007

Sponsored by: Poniard Pharmaceuticals
Information provided by: Poniard Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00465725
Purpose

Picoplatin is a new platinum-based chemotherapy drug that has been studied
in a variety of cancers. Phase 1 and 2 studies have demonstrated that
picoplatin may be effective in patients whose cancer returns or does not
improve after treatment with chemotherapy. In these studies, picoplatin
was administered intravenously. A capsule containing picoplatin has been
formulated. This study will investigate the activity of the oral capsule
in humans. Participants with advanced solid tumors will be enrolled.
Condition Intervention Phase I
Bladder Cancer
Breast Cancer
Colorectal Cancer
Gastrointestinal Neoplasm
Head and Neck Cancer
Lung Cancer
Ovarian Cancer
Pancreatic Cancer
Prostate Cancer

Study Start Date: April 2007
Estimated Study Completion Date: September 2007
I guess it's closed...
" 5/15/08 - Poniard to Present Clinical Data From Picoplatin Trials in
Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual
Meeting", so doubtful it's still recruiting, but they're testing it on
other types of cancer.
" 5/06/08 - Poniard Pharmaceuticals Completes Enrollment of Phase 2
Picoplatin Trial in Colorectal Cancer"

J